ZNF878

Across TCGA pan-cancer cohorts, ZNF878 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ZNF878 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher ZNF878 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF878 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

READ, LUSC, and COAD are the cancer types where ZNF878 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	III,IV	0.462	0.913	<.001	39	view →
LUSC	OS	Median	All	0.211	0.777	.001	24	view →
COAD	OS	Median	All	0.144	0.799	.001	20	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	DFS	Median	All	0.973	0.828	.020	6	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	All	1.000	0.312	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ZNF878–READ (OS)

Open the READ breakdown →